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serious public health problem worldwide, as more than
two billion people have been infected and 350 million
are chronically infected [1,2]. Chronicity rates vary
based on routes of exposure, with a chronicity rate of
5% in adult acquisition versus 90% in newborns [3].
15–40% of chronically infected patients will develop
adverse sequelae including cirrhosis, hepatic decompen-
sation, and hepatocellular carcinoma [4–6].
Hepatocellular carcinoma (HCC), a potentially seri-
ous late complication of HBV infection, is now the ﬁfth
most common malignancy worldwide, especially in Asia
and Africa [7,8]. The risk of developing HCC in patients
with cirrhosis due to chronic HBV is about 1.5% per year
[8,9]. AlthoughHCC ismore common in the setting of cir-
rhosis, with data showing that approximately 75% of
HCC cases occur in patients with cirrhosis, cirrhosis
may not necessarily precedeHCC inHBV-infected people
[10]. Zaman et al. in their study of 448 patients withHBV-
associated HCC identiﬁed that in 70% of cases, HCC was
diagnosed before cirrhosis was recognized [8,10]. As the
prognosis of patients with late stage HCC is often grim,
earlier detection of small tumors oﬀers the potential for
curative therapy. Hence, screening of high-risk popula-
tions has been recommended and various strategies have
been advocated in an eﬀort to identify and eﬀectively treat
early HCC and improve overall mortality.0168-8278 2008 Published by Elsevier B.V. on behalf of the European As
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factors for the development of HCC plays an important
role in prevention. As the global burden ofHBV infection
is enormous, it is virtually impossible to screen all infected
patients forHCC.Therefore, the identiﬁcation of risk fac-
tors, target populations, andpredictivemodels are needed
to help focus screening to the infected population that is
most at risk for the development of HCC. In this issue
of the Journal of Hepatology, Yuen et al. [11] attempt
not only to identify the risk factors for HCC in patients
with HBV, but also to develop a predictive risk score for
patients at high risk for development of HCC.
In this longitudinal study over a period of 10 years,
820 treatment naı¨ve patients with chronic HBV were fol-
lowed at a liver clinic at Queen Mary’s Hospital in Hong
Kong. These patients were followed every 3–6 months,
and were monitored with HBV serology, liver biochem-
istry, and alpha-fetoprotein. Patents underwent radio-
logic imaging only if AFP levels were greater than
20 ng/mL. The primary endpoint was a diagnosis of
HCC by either a positive histology or elevated AFP lev-
els with imaging compatible with HCC.
Of the 820 patients followed, 40 (4.9%) developed
hepatocellular carcinoma. After analysis of the collected
data, Yuen et al. [11] identiﬁed various virological and
host risk factors for the development of HCC. In univar-
iate analysis, male gender, older age, higher HBV DNA
levels, presence of core promoter mutations, ALT >0.5
X ULN, and pre-existing cirrhosis were signiﬁcant risk
factors for the development of HCC. Of the other indi-
ces, such as comparing genotype B and C, precore and
wild-type mutations, HBeAg/anti-HBe status on presen-
tation, and HBeAg/anti-HBe seroconversion, no diﬀer-
ence in the risk of HCC was found. Combining these
data in a multivariable Cox Regression model, male gen-sociation for the Study of the Liver. Open access under CC BY-NC-ND license.
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DNA levels (HR 1.28), core promoter mutations (HR
3.66), and presence of cirrhosis (HR 7.31) were indepen-
dently associated with the development of HCC.
With these independent associations, Yuen et al. [11]
then created a predictive scoring system for the develop-
ment of HCC by using a logistic regression equation
including gender, age, HBV DNA, cirrhosis, and core
promoter mutation. This scoring system, the ‘‘Guide
with Age, Gender, HBV DNA, Core promoter muta-
tions and Cirrhosis” (GAGHCC), attempts to predict
the 5- and 10-year risk of development of HCC. The
optimal cut-oﬀ of the HCC score for the prediction of
5- and 10-year development of HCC is 101, and once
this threshold is reached, the risk increases exponen-
tially. As core promoter mutations are not typically ana-
lyzed in clinical practice, Yuen et al. [11] then
reformulated, tested, and had similar results in this pre-
dictive scoring system without the use of core promoter
mutations.
As HBV and HCC are major global problems, early
identiﬁcation of high-risk populations with the utiliza-
tion of a validated scoring system allows for signiﬁcant
streamlining of screening modalities. However in this
study, there were only 40 cases of HCC. Thus Yuen
et al. [11] may have oversaturated their regression model
with the analysis of six variables. Additionally, the
authors validated the GAGHCC predictive score by per-
forming the leave-one-out cross validation analysis. This
method, although mathematically sound, is still not as
eﬀective as validation in another cohort of patients.
Hence, further validation needs to be performed on
other populations, including both high-risk and low-risk
patients.
It is reassuring that the risk factors identiﬁed by Yuen
et al. [11] have been shown in other studies to be associ-
ated with HCC. Interestingly, HBeAg status and HBV
genotype were not found to be signiﬁcantly associated
with HCC in their model. In contrast to these results,
Yang et al. in a prospective population-based study fol-
lowing 11,893 men for the development of hepatocellular
carcinoma reached diﬀerent conclusions [12]. They identi-
ﬁed that the incident rate of HCC was approximately 3-
fold higher in individuals who were positive for both
HBsAg and HBeAg, as compared to men who were posi-
tive for HBsAg and negative for HBeAg [12].
Yuen et al. [11] also found no diﬀerence in the cumu-
lative risk of HCC when comparing patients with geno-
type B or C. Previous studies suggested a diﬀerence in
HCC risk based on genotypes. In a prospective cohort
study of 1006 patients in Hong Kong, where 86 devel-
oped HCC, genotype C was independently associated
with a higher risk of HCC than genotype B (HR:3.83;
95% CI, 2.15 to 6.81; P < .0001) [13]. In the current
paper, Yuen et al. [11] made the argument that as basal
core promoter (BCP) mutations are more common ingenotype C, it is the BCP mutation that is the actual risk
factor for HCC rather than genotype. However, in
another study controlling for BCP status, Yang et al.
showed that genotype C was an independent risk factor
for HCC [14]. As genotyping and mutation analysis
become more available, this issue will need to be
clariﬁed.
Yuen et al. [11] derived this scoring system from a
cohort of Chinese patients in a hospital liver clinic,
which could contribute to a selection bias. As the inci-
dence of HCC diﬀers by race [3,15], it is unclear if this
scoring system will be applicable to the non-Asian pop-
ulation. Clearly, future validation studies are needed in
patients from diﬀerent regions and other ethnicities.
With validation, this ‘‘GAGHCC” scoring system may
become a helpful screening tool.
In the past two decades, we have made great strides in
addressing chronicHBV infection as a global health prob-
lem. The success of HBV vaccination in various parts of
the world has reduced the prevalence of infection, and
ultimately, hepatocellular carcinoma [16]. However,
much work is still needed in this ﬁeld, as there is a huge
demand for HCC surveillance. The ability for risk strati-
ﬁcation of patients with HBV in predicting HCC not only
addresses important public health issues, but also pro-
vides a rationale for resource allocation in health care.
Yuen et al. [11] have attempted to consolidate the work
of many in an eﬀort to ‘‘push the envelope” even further.
After identiﬁcation of various independent risk factors
for the development of HCC in the setting of chronic
HBV, they introduce a novel predictive scoring system
for the development of HCC. This scoring system com-
bines each of the individual risk factors together to obtain
an estimate of the overall risk for an individual patient.
The future of the ﬁght against chronic HBV and
HCC appears to be a bright one, as the ﬁeld of medicine
continues to evolve. The move towards genomic medi-
cine with the application of genome wide association
studies will hopefully identify genetic factors that predis-
pose HBV patients to the development HCC. The com-
bination of genetic information in conjunction with a
validated predictive scoring system based on various
clinical parameters may promise a more personalized
approach to medicine, ultimately leading to improved
patient care.References
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